INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jul 23, 2026

Can ARS Pharma's New CEO Unlock Neffy's Potential?

On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026.

Benzinga • Jul 9, 2026

ARS Pharmaceuticals Announces CEO Succession

Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of  Leadership Since Co-Founding the Company

GlobeNewsWire • Jul 7, 2026

ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky

ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contradicted repeated executive coverage projections. NEW YORK, July 6, 2026 /PRNewswire/ -- Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched more than 23% of their investment disappear on June 24, 2026, when the Company disclosed that Neffy® received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle.

PRNewsWire • Jul 6, 2026

SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy® received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors who lost money on SPRY are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.

Business Wire • Jul 1, 2026

ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals CEO projected CVS Caremark formulary inclusion was expected for the July 1, 2026 commercial formulary cycle -- the July 2026 payer cycle produced zero new formulary additions, and SPRY fell more than 23%. NEW YORK, June 29, 2026 /PRNewswire/ -- Investors in ARS Pharmaceuticals (NASDAQ: SPRY) lost more than 23% of their investment value in after-hours trading on June 24, 2026, after the Company disclosed that Neffy® -- its flagship epinephrine nasal spray -- received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle.

PRNewsWire • Jun 29, 2026

SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.

Business Wire • Jun 28, 2026

ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January

ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.

Investors Business Daily • Jun 25, 2026

ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow breakeven in 2027, even as no additional commercial formulary decisions for its epinephrine nasal spray Neffy were secured during the July 1, 2026 coverage cycle.

Benzinga • Jun 25, 2026

ARS Pharmaceuticals Provides Commercial and Financial Updates

No new commercial formulary additions or coverage decisions issued for  neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion

GlobeNewsWire • Jun 24, 2026